Back to results

CompletedPhase 4

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

NCT01574170

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

C.M.C.O. Claude Bernard

Albi, France

+15 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2012-06-18
Enrollment: 267 participants
Sponsor: Institut Claudius Regaud
Purpose: other

Locations (16)

C.M.C.O. Claude BernardAlbi, France
Institut de Cancérologie de l'Ouest Paul PapinAngers, France
CHU Jean MinjozBesançon, France
CHRU BrestBrest, France
Centre Hospitalier Jean RougierCahors, France
Centre Hospitalier Intercommunal de Castres-MazametCastres, France
Centre d'Oncologie et de Radiothérapie du ParcDijon, France
Centre Georges François LeclercDijon, France
Clinique La Croix du SudQuint-Fonsegrives, France
Centre Eugène MarquisRennes, France
Centre Hospitalier de RodezRodez, France
Centre Paul StraussStrasbourg, France
Polyclinique de l'OrmeauTarbes, France
CHU RangueilToulouse, France
Institut Claudius RegaudToulouse, France
Institut de Cancérologie de LorraineVandœuvre-lès-Nancy, France

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival — TrialFind